Back to top

Image: Bigstock

AZEK: Strong Industry, Solid Earnings Estimate Revisions

Read MoreHide Full Article

One stock that might be an intriguing choice for investors right now is The AZEK Company Inc. (AZEK - Free Report) . This is because this security in the Building Products - Air Conditioner and Heating space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.

This is important because, often times, a rising tide will lift all boats in an industry, as there can be broad trends taking place in a segment that are boosting securities across the board. This is arguably taking place in the Building Products - Air Conditioner and Heating space as it currently has a Zacks Industry Rank of 34 out of more than 250 industries, suggesting it is well-positioned from this perspective, especially when compared to other segments out there.

Meanwhile, AZEK is actually looking pretty good on its own too. The firm has seen solid earnings estimate revision activity over the recent past, suggesting analysts are becoming a bit more bullish on the firm’s prospects in both the short and long term.

In fact, over the past two months, current quarter estimates have risen from 13 cents per share to 24 cents per share, while current year estimates have risen from 49 cents per share to 61 cents per share. This has helped AZEK to earn a Zacks Rank #2 (Buy), further underscoring the company’s solid position. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

So, if you are looking for a decent pick in a strong industry, consider AZEK. Not only is its industry currently in the top third, but it is seeing solid estimate revisions as of late, suggesting it could be a very interesting choice for investors seeking a name in this great industry segment.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>


See More Zacks Research for These Tickers


Normally $25 each - click below to receive one report FREE:


The AZEK Company Inc. (AZEK) - free report >>

Published in